Trials / Recruiting
RecruitingNCT06240546
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LPM6690176 Capsules in Patients With Advanced Solid Tumors.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- Luye Pharma Group Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LPM6690176 | Administered orally |
Timeline
- Start date
- 2024-03-12
- Primary completion
- 2026-02-01
- Completion
- 2027-02-01
- First posted
- 2024-02-05
- Last updated
- 2024-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06240546. Inclusion in this directory is not an endorsement.